middle.news
How Immutep’s A$30M Deal with Dr. Reddy’s Accelerates Cancer Immunotherapy Trials
11:52am on Thursday 29th of January, 2026 AEDT
•
Biotechnology
Read Story
How Immutep’s A$30M Deal with Dr. Reddy’s Accelerates Cancer Immunotherapy Trials
11:52am on Thursday 29th of January, 2026 AEDT
Key Points
A$30 million upfront payment from Dr. Reddy’s for eftilagimod alfa commercialisation outside key markets
Potential milestone payments up to A$528 million plus royalties
Phase III lung cancer trial TACTI-004 progressing with futility analysis on track
Positive efficacy data from soft tissue sarcoma and breast cancer trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMM
OPEN ARTICLE